Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:CORT.O 1 January 2026

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics shares plunged 50.4% to $34.80 on Dec. 31 after the FDA declined to approve relacorilant for hypercortisolism-related hypertension, citing insufficient evidence of effectiveness. Wolfe Research downgraded the stock to Underperform with a $30 target. Trading was briefly halted before resuming with heavy volume. The FDA set a separate July 2026 decision date for relacorilant in ovarian cancer.
1 January 2026
··

Stock Market Today

  • Fundrise Lists Venture-Focused Innovation Fund VCX on NYSE
    March 20, 2026, 7:55 PM EDT. Fundrise, an online investment platform, has launched its Fundrise Innovation Fund (VCX) on the New York Stock Exchange (NYSE). This marks the first publicly traded venture fund from Fundrise, opening access to individual investors regardless of wealth. Top holdings include private companies like Anthropic, OpenAI, SpaceX, and Epic Games. VCX has a 1.85% management fee and began trading recently, though it was launched in July 2022. Since inception, VCX has achieved an 84.44% return, with a 13.43% gain year-to-date. Initial trading prices are around $120 per share. Fundrise's move into venture funds complements its roots in real estate crowdfunding and presents a new liquidity avenue for private securities owners.
Go toTop